艾达拉的不良事件报告:来自FAERS数据库的现实世界分析
Qi Shang1, Jie Zhou2, Junchang Ye3
1Department of Pharmacy, Fujian Provincial Geriatric Hospital, Fuzhou, Fujian, 350000, People's Republic of China.
Scientific reports
|March 10, 2025
概括
这项研究分析了食品和药物管理局关于edaravone的不良事件报告,edaravone是一种肌缩性侧面硬化症 (ALS) 治疗. 它确定了潜在的新不良事件,包括肝功能障碍和血栓形成,这些不列在药物中.
科学领域:
- 药物监督 药物监督 药物监督
- 神经学 神经学
- 药品安全 药品安全
背景情况:
- 静脉注射埃达拉是一种已批准的疾病修饰疗法,用于肌缩侧面硬化症 (ALS).
- 随着埃达拉的使用,已报告了许多不良事件 (AE).
- 现实世界的数据分析对于理解药物安全性概况至关重要.
研究的目的:
- 通过使用大规模的真实世界数据库,调查和量化与edaravone相关的不良事件.
- 识别药物插件中以前未记录的潜在的新安全信号.
- 为加强edaravone的临床监测和风险评估提供证据.
主要方法:
- 利用了2017年4月至2024年3月的食品和药物管理局不良事件报告系统 (FAERS) 的数据.
- 提取了2986份报告,其中埃达拉是主要的可疑药物.
- 采用多种定量方法,包括MGPS,BCPNN,ROR和PRR来检测AE信号.
主要成果:
- 埃达拉与27个器官系统类别的不良事件有关.
- 确定了药物插件中未列出的意想不到的严重副作用,例如肝功能异常,导管部位血栓,脑出血和脑静脉鼻腔血栓.
- 发现了需要进一步调查的潜在新安全信号.
结论:
- 这项研究确定了艾达拉在肌缩性侧面硬化症患者中潜在的新不良事件信号.
- 这些发现支持需要更新edaravone的临床监测和风险管理策略.
- 需要进一步的研究来验证这些新发现的副作用在现实世界的临床实践中.
更多相关视频
相关概念视频
Pharmacovigilance
764
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
764
Hazard Ratio
73
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
73
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
360
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
360
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Antiepileptic Drugs: Potassium Channel Activators
140
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
140


